Stock Price Movement and Market Context
On 24 Nov 2025, Epigral's share price touched an intraday low of Rs.1428, representing a fall of 2.08% during the trading session. This decline contributed to an overall day change of -1.87%, underperforming its sector by 0.85%. The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum.
In contrast, the broader market benchmark, the Sensex, opened 88.12 points higher and was trading at 85,343.57, up 0.13%. The Sensex remains close to its 52-week high of 85,801.70, just 0.54% away, supported by a three-week consecutive rise and leadership from mega-cap stocks. The Sensex is also trading above its 50-day moving average, which itself is positioned above the 200-day moving average, indicating a bullish trend in the broader market.
Long-Term and Recent Performance Analysis
Epigral's one-year performance shows a decline of 26.32%, contrasting sharply with the Sensex's gain of 7.85% over the same period. The stock's 52-week high was Rs.2195.85, highlighting the extent of the recent price erosion. Over the last three years, one year, and three months, Epigral has underperformed the BSE500 index, reflecting challenges in maintaining competitive returns.
Financially, the company’s operating profit has shown a negative compound annual growth rate of 5.49% over the past five years. The latest quarterly results for September 2025 reveal a mixed picture: interest expenses for the last six months stood at Rs.45.21 crores, representing a growth of 286.41%, while the quarterly profit after tax (PAT) was Rs.51.22 crores, down by 52.6% compared to the average of the previous four quarters. The operating profit to net sales ratio for the quarter was recorded at 22.53%, the lowest in recent periods.
Strong fundamentals, steady climb upward! This Large Cap from Telecommunication sector earned its Reliable Performer badge through consistent execution. Safety meets solid returns here!
- - Reliable Performer certified
- - Consistent execution proven
- - Large Cap safety pick
Financial Strength and Valuation Metrics
Despite the recent price decline, Epigral exhibits certain financial strengths. The company’s return on capital employed (ROCE) stands at a robust 23.19%, indicating efficient use of capital in generating profits. Additionally, the debt servicing capacity appears sound, with a low Debt to EBITDA ratio of 1.34 times, suggesting manageable leverage levels.
Valuation metrics also provide some context: the company’s ROCE of 19.3% aligns with a fair valuation, supported by an enterprise value to capital employed ratio of 2.6. The stock is trading at a discount relative to its peers’ average historical valuations. Over the past year, while the stock price has declined by 26.32%, the company’s profits have risen by 37.1%, resulting in a price/earnings to growth (PEG) ratio of 0.5, which may reflect market caution despite improving profitability.
Shareholding and Sector Position
Epigral operates within the Specialty Chemicals industry and sector, where it faces competitive pressures and sector-specific dynamics. The majority shareholding rests with promoters, providing a degree of ownership stability. However, the stock’s recent performance relative to sector peers and the broader market has been subdued.
Considering Epigral ? Wait! SwitchER has found potentially better options in Specialty Chemicals and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - Specialty Chemicals + beyond scope
- - Top-rated alternatives ready
Summary of Key Concerns
The stock’s fall to Rs.1428, its lowest level in 52 weeks, reflects a combination of factors including subdued long-term growth in operating profit, a significant rise in interest expenses, and a sharp decline in quarterly profits. The operating profit margin to net sales ratio at 22.53% is the lowest recorded recently, signalling margin pressures. These elements have contributed to the stock’s underperformance relative to the Sensex and the Specialty Chemicals sector.
Trading below all major moving averages further underscores the current downward trend in the stock price. While the broader market and sector indices show resilience and positive momentum, Epigral’s share price has not mirrored these trends, indicating company-specific challenges.
Market Environment and Sector Dynamics
The Specialty Chemicals sector, in which Epigral operates, is subject to fluctuations driven by raw material costs, regulatory changes, and demand cycles. While the Sensex and mega-cap stocks have shown strength recently, smaller and mid-cap stocks like Epigral have faced headwinds. The stock’s discount valuation compared to peers suggests that the market is factoring in these challenges.
Conclusion
Epigral’s stock reaching a 52-week low of Rs.1428 highlights the pressures faced by the company amid a generally positive market backdrop. The combination of financial metrics, including a decline in quarterly profits, rising interest costs, and subdued long-term operating profit growth, has contributed to this price level. The stock’s position below key moving averages and its underperformance relative to the Sensex and sector peers provide a comprehensive picture of its current market standing.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
